微小RNA-126-3p在不同免疫表型乳腺癌组织的表达及临床意义  

Expression and clinical significance of microRNA -126 -3p in breast carcinomas with different im- munohistochemical profiling

作　　者：李丽琴[1] 李静[1] 平金良[2] 黄惠莲[1] 钟婧[1] 戴利成[1] 

机构地区：[1]浙江省湖州市中心医院中心实验室,313000 [2]浙江省湖州市中心医院病理科,313000

出　　处：《中华实验外科杂志》2016年第12期2752-2755,共4页Chinese Journal of Experimental Surgery

基　　金：浙江省自然科学基金（LQl2H16002）;湖州市公益性技术应用研究（重点）项目（2013GZ13）;国家科技重大新药创制专项（2013ZX09102051）

摘　　要：目的探讨在4种不同免疫表型的乳腺癌中微小RNA（miRNA，miR）-126-3p在组织的表达，并分析其临床意义。方法应用实时荧光定量聚合酶链反应（FQ-PCR）方法检测67例乳腺癌组织及其癌旁组织中miR-126-3p表达量，进一步应用组织芯片-原位杂交方法检测140例乳腺癌组织中miR-126-3p的表达量。结果FQ-PCR显示miR-126-3p在癌组织中表达量低于癌旁组织，且在三阴性乳腺癌中表达量最低，但是差异无统计学意义。组织芯片-原位杂交方法可见miR-126-3p主要在肿瘤组织基质中表达，高于良性纤维瘤（χ2=21．48，P〈0．01）。miR-126-3p在三阴性乳腺癌基质中表达量最低（高表达率60％），人表皮生长因子受体-2（Her-2）过表达组中表达量最高（高表达率91．3％），且两组差异有统计学意义（χ2=6．26；P〈0．05）。组织病理学证据也表明Her-2蛋白的表达量与miR-126-3p的表达呈正相关（χ2=5．73，P〈0．05）。结论miR-126-3p在肿瘤基质中的表达量在不同免疫表型之间差异有统计学意义，能为乳腺癌的个体化诊断和治疗提供潜在靶点．Objective To investigate the expression of microRNA （miRNA, miR） - 126 -3p in breast carcinomas with four different immunohistoehemical profiling and their relevance to clinicopathologic features. Methods The expression of miR - 126 -3p was detected by real - time fluorescent quantitative polymerase chain reaction （ FQ - PCR） in 67 paired frozen breast carcinomas tissues and further detected by TMA- ISH in 140 cases of formalin fixed paraffin- embedded （FFPE） breast carcinomas tissues. Re- suits MiR - 126 - 3p expression level was lower in carcinoma tissues than that in paired para - cancerous tissues, and lowest in triple - negative breast cancer （TNBC） immune phenotype without significant differ- ence using FQ - PCR method. The results of TMA - ISH showed that miR - 126 - 3p was mainly expressed in stroma of tumor tissue, and its expression level was higher in tumor tissue than that in breast fibroadeno- mas （χ2 =21.48,P 〈0. 01）. Triple-negative breast cancers in stroma showed the lowest miR -126 -3p expression level （high expression rate of 60% ）, and human epidermal growth factor receptor - 2 （Her- 2） over- expressed group showed the highest expression level （high expression rate of 91.3% ） within four subtypes, which had the significant differences （χ2 = 6. 26 ; P 〈 0. 05 ）. Furthermore, strong miR - 126 - 3p expression was significantly associated with Her - 2 expression （χ2 = 5.73, P 〈 0. 05 ）. Conclusion There was a difference in the miR - 126 - 3p expression in breast tumor between different im- mune phenotypes, which may be used as a potential individual diagnostic and drug target for breast cancer patients.

关 键 词：乳腺癌 微小RNA-126-3p 人表皮生长因子受体-2过表达 

分 类 号：R737.9[医药卫生—肿瘤]